Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302247 · ClinicalTrials.gov registry record · Phase 2
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03302247 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT03302247, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells, thereby increasing the efficacy of Nivolumab.
Interventions
- BIOLOGICAL Nivolumab
- DRUG Nivolumab+Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2019-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302247
The ClinicalTrials.gov registry entry for NCT03302247 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03302247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03302247 about?
NCT03302247 is a clinical study titled "Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy". Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeu...
What is the current status of trial NCT03302247?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-01-15. Estimated completion is 2019-07-12.
What interventions are being tested in trial NCT03302247?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nivolumab+Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03302247?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.